Aspirin at any dose above 30 mg daily prevents 13% of vascular events (95% CI 4-21) compared to control, with virtually no difference in relative risk reduction across low, medium, and high doses.
Meta-Analysis (n=6,171)
Does aspirin at different doses prevent vascular events in patients after a transient ischaemic attack or non-disabling stroke?
Aspirin provides a modest 13% relative risk reduction in vascular events after TIA or non-disabling stroke, with no significant difference in efficacy between low, medium, and high doses.
Effect estimate: RRR 13% (95% CI 4-21)
There is continuing debate about the relative efficacy of low ( 900 mg per day) doses of aspirin in patients after a transient ischaemic attack or non-disabling stroke. The purpose of this study was to resolve the issue. Thus a minimeta-analysis was performed on data from 10 randomised trials of aspirin only v control treatment in 6171 patients after a transient ischaemic attack or nondisabling stroke. The data on the trials were listed in an appendix of the report on the second cycle of the Antiplatelet Trialists' Collaboration. There was virtually no difference in relative risk reduction for low, medium, and high doses of aspirin (13%, 9%, and 14% respectively). This equivalence corresponds with the results of the UK-TIA trial in a direct comparison of 300 and 1200 mg. The Dutch TIA trial showed no difference in efficacy of 30 and 283 mg. It is concluded that aspirin at any dose above 30 mg daily prevents 13% (95% confidence interval 4-21) of vascular events and that there is a need for more efficacious drugs.
Algra et al. (Thu,) conducted a meta-analysis in Transient ischaemic attack or non-disabling stroke (n=6,171). Aspirin vs. Control treatment was evaluated on Vascular events (RRR 13%, 95% CI 4-21). Aspirin at any dose above 30 mg daily prevents 13% of vascular events (95% CI 4-21) compared to control, with virtually no difference in relative risk reduction across low, medium, and high doses.